Genocea Biosciences Inc. (NASDAQ:GNCA): Begins Phase II Trial for Immunotherapy Candidate GEN-003


Dallas, Texas 07/21/2014 (FINANCIALSTRENDS) – Genocea Biosciences Inc. (NASDAQ:GNCA) today announced to commence a Phase II dose optimization study for its immunotherapy candidate GEN-003 which is indicated for the treatment of HSV-2 (herpes simplex-type 2). The management believes that there is significant medical need for an effective immunotherapy for HSV-2. The Company’s market research revealed that both physicians and patients would welcome a new treatment like GEN-003 with enhanced convenience of dosing, sustained duration of protection and efficacy similar to oral antivirals. This dose optimization trial will compare the best dose of GEN-003 from the Company’s Phase I/IIa clinical trial to other combinations of protein and adjuvant to estimate optimal dose for future trials.

About Phase II Trial

Chief Medical Officer of Genocea Biosciences Inc. (NASDAQ:GNCA), Dr. Seth Hetherington expressed that the Phase II trial builds on Phase I/IIa clinical trial whereby the company’s therapeutic vaccine demonstrated anti-viral effect. The Phase II study will enroll approximately 300 subjects from 17 sites across the U.S. In this placebo-control trial, all subjects will receive placebo or three doses of GEN-003 at 21-day intervals. The primary endpoint is the change in viral shedding rate as compared to baseline. The study will also assess the impact on a percentage of days with genital herpes lesions as reported by the subject. Patients receiving GEN-003 will be followed for 12 months following the last dose.

Company Brief

Genocea Biosciences Inc. (NASDAQ:GNCA) is a development stage biopharmaceutical company engaged in the development of T cell-enable immunotherapies and vaccines. The company utilizes its proprietary technology platform ATLAS™ to identify the targets to enable the rapid development of medicines that can trigger protective immune responses. The Company’s pipeline portfolio includes GEN-003 for HSV-2 therapy and GEN-004 for pneumococcus infections. The early stage programs of the company include testing of candidates for potential therapy of malaria, HSV-2 prophylaxis, chlamydia and cancer immunotherapy.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.